Table 2.
The prevalence of precancer and cancer among patients with atypical glandular cells with and without concurrent squamous cell abnormalities according to hrHPV types.
| Group | Squamous lesions | Glandular lesions | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| hrHPV | Total | HSIL+, No. (%) | p | SCC, No. (%) | p | AIS+/AEH+, No. (%) | p | AC, No. (%) | p | |
| AGC + Sq | negative | 26 | 1 (3.9%) | 0.276 | 0 | NS | 5 (19.2%) | 0.629 | 4 (15.4%) | 0.804 |
| 16+ | 3 | 1 (33.3%) | 0 | 1 (33.3%) | 1 (33.3%) | |||||
| 18+ | 0 | 0 | 0 | 0 | 0 | |||||
| Other+ | 6 | 0 | 0 | 2 (33.3%) | 1 (16.7%) | |||||
| 16+, 18+ | 1 | 0 | 0 | 0 | 0 | |||||
| Total | 36 | 2 (5.6%) | 0 | 8 (22.2%) | 6 (16.7%) | |||||
| AGC-Alone | negative | 514 | 3 (0.6%) | <0.0001 | 0 | <0.0001 | 51 (9.9%) | <0.0001 | 38 (7.4%) | 0.0043 |
| 16+ | 25 | 8 (32.0%) | 2 (8.0%) | 7 (28.0%) | 4 (16.0%) | |||||
| 18+ | 20 | 4 (20.0%) | 2 (10.0%) | 10 (50.0%) | 3 (15.0%) | |||||
| Other+ | 74 | 6 (8.1%) | 1 (1.4%) | 3 (4.1%) | 3 (4.1%) | |||||
| 16+, 18+ | 1 | 0 | 0 | 1 (100%) | 1 (100%) | |||||
| Total | 634 | 21 (3.3%) | 5 (0.8%) | 72 (11.4%) | 53 (8.4%) | |||||
| AGC | negative | 540 | 4 (0.7%) | <0.0001 | 0 | <0.0001 | 56 (10.4%) | <0.0001 | 42 (7.8%) | 0.0089 |
| 16+ | 28 | 9 (32.1%) | 2 (7.1%) | 8 (28.6%) | 5 (17.9%) | |||||
| 18+ | 20 | 4 (20.0%) | 2 (10.0%) | 10 (50.0%) | 3 (15.0%) | |||||
| Other+ | 80 | 6 (7.5%) | 1 (1.3%) | 5 (6.3%) | 4 (5.0%) | |||||
| 16+, 18+ | 2 | 0 | 0 | 1 (50%) | 1 (50%) | |||||
| Total | 670 | 23 (3.4%) | 5 (0.8%) | 80 (11.9%) | 59 (8.8%) | |||||
AC, adenocarcinoma; AEH, atypical endometrial hyperplasia; AGC, atypical glandular cell; AGC + Sq, atypical glandular cells with concurrent squamous cell abnormalities; AGC-alone, atypical glandular cells without concurrent squamous cell abnormalities; AIS, cervical adenocarcinoma in situ; hrHPV, high risk human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; NS, not significant.